<table className="table">
  <caption>
    <p>
      Targeted Therapies for Validated Genomic Alterations in Metastatic Lung Cancer
    </p>
  </caption>
  <thead>
    <tr>
      <th rowSpan="1" colSpan="1">
        <p>
          Gene/Alteration
        </p>
      </th>
      <th rowSpan="1" colSpan="1">
        <p>
          Potentially Active Drugs (Not All Inclusive or in Order of Preference)
        </p>
      </th>
    </tr>
  </thead>
  <tbody>
    <tr className="group_1-1 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            EGFR
          </i>
          , various alterations
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Afatinib, osimertinib, erlotinib, amivantamab, lazertinib
        </p>
      </td>
    </tr>
    <tr className="group_1-2 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            EGFR
          </i>
          , exon 20 insertion
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Amivantamab, mobocertinib
        </p>
      </td>
    </tr>
    <tr className="group_1-3 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            KRAS
          </i>
          G12C mutation
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Sotorasib
        </p>
      </td>
    </tr>
    <tr className="group_1-4 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          ALK rearrangement (gene fusion)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Alectinib, brigatinib, ceritinib, ensartinib, lorlatinib
        </p>
      </td>
    </tr>
    <tr className="group_1-5 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            ROS1
          </i>
          rearrangement (gene fusion)
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Ceritinib, crizotinib, entrectinib, lorlatinib
        </p>
      </td>
    </tr>
    <tr className="group_1-6 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            BRAF
          </i>
          V600E mutation
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Dabrafenib/trametinib, vemurafenib
        </p>
      </td>
    </tr>
    <tr className="group_1-7 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            NTRK
          </i>
          1, 2, or 3 gene fusion
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Larotrectinib, entrectinib
        </p>
      </td>
    </tr>
    <tr className="group_1-8 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            MET
          </i>
          exon 14 skipping mutation
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Capmatinib, crizotinib, tepotinib
        </p>
      </td>
    </tr>
    <tr className="group_1-9 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            RET
          </i>
          rearrangement
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Selpercatinib, pralsetinib, cabozantinib
        </p>
      </td>
    </tr>
    <tr className="group_1-10 row-even">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            ERBB2
          </i>
          (
          <i>
            HER2
          </i>
          ) mutation positive
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Fam-trastuzumab deruxtecan, ado-trastuzumab emtansine
        </p>
      </td>
    </tr>
    <tr className="group_1-11 row-odd">
      <td rowSpan="1" colSpan="1">
        <p>
          <i>
            NRG1
          </i>
          gene fusion
        </p>
      </td>
      <td rowSpan="1" colSpan="1">
        <p>
          Zenocutuzumab-zbco (after progression on first-line treatment)
        </p>
      </td>
    </tr>
  </tbody>
</table>
